Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system for which more than 20 disease-modifying therapies (DMTs) are currently available. Recent advances in diagnostic criteria, biomarker development, and understanding of disease biology have challenged traditional phenotype-based treatment paradigms and created new opportunities for individualized therapeutic strategies. The 2024 McDonald diagnostic criteria expand the biological definition of MS through incorporation of advanced MRI biomarkers, thereby supporting earlier diagnosis and potentially earlier treatment initiation. Aging influences both disease pathobiology and treatment risk–benefit balance, contributing to reduced focal inflammatory activity, increased progression, diminished regenerative capacity, and greater susceptibility to infections and comorbidities. These observations have important implications for treatment initiation, sequencing, escalation, de-escalation, and discontinuation. Current monitoring strategies remain centered on relapses, disability measures, and MRI lesion activity, but each has important limitations. Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed. Safety considerations vary substantially across DMT classes. Real-world data have advanced our understanding of long-term risks, particularly with B-cell-depleting therapies. Novel therapeutic approaches in development are intended to more effectively target compartmentalized central nervous system inflammation and progression biology while potentially reducing systemic immunosuppression. As a result of these factors, MS management is evolving.
Multiple sclerosis is now diagnosed and treated earlier than in previous therapeutic eras, but the clinical value of this shift depends on whether earlier recognition leads to prevention of irreversible disability rather than simply earlier labeling of disease. This narrative review examines the relationship among cont...
Bárbara Alexandra Ossuchi de Oliveira, Laura Leme de Araújo Rodrigues da Silva, Luísa Craide Haenssgen et al.· International Health Science...· 0 citations
Introduction and purpose: Multiple Sclerosis (MS) disability accumulation is driven primarily by compartmentalized, subclinical neuroinflammation and diffuse neurodegeneration, termed smouldering MS. While traditional disease-modifying therapies (DMTs) control peripheral relapses and focal MRI activity, halting this pr...
Natalia Kitala, Justyna Karliczek, K. Nycz et al.· International Journal of Inn...· 0 citations
Background: Multiple sclerosis (MS) is a disease whose incidence has been increasing statistically alongside the development and wider availability of advanced diagnostic methods. Despite extensive research investigating its etiology, clinical course, and therapeutic approaches, considerable uncertainty remains regardi...
Bartosz Seroczyński, Anna Zyskowska, Gabriela Pyrka et al.· Quality in Sport· 0 citations
Multiple sclerosis (MS) care has advanced rapidly across diagnosis, biomarkers, and disease-modifying therapy. The 2024 revision of the McDonald criteria enables earlier and more biologically grounded diagnosis through the cerebrospinal fluid (CSF) kappa free light chain (KFLC) index, the central vein sign (CVS), and p...
Ethan Grund, Anne H. Cross, S. Chahin· Journal of Neuroimmunology· 0 citations
This review focuses on some of the groundbreaking advances and the immediate challenges faced by researchers, clinicians, and individuals with PD, as they collaborate to address the great-and ever-growing-clinical need in PD.
Grażyna Söderbom· International review of neur...· 0 citations
The characteristic MRI features of MS SC lesions and their key inflammatory and non-inflammatory differentials are described, and the role of SC imaging in diagnosis is examined, particularly in the context of the 2024 revisions to the McDonald criteria.
T. Koren, Jashan Dugal, Dong-Ang Wang et al.· Journal of Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.